Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Ascentage ASCENTAGE PHARMA GROUP INTERNATIONAL 亞 盛 醫藥 集團 ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 6855 ) ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30 , 2026 The Board is pleased to announce the unaudited consolidated results of Ascentage Pharma Group International for the six months ended June 30 , 2026 , together with the comparative figures for the six months ended June 30 , 2025 . FINANCIAL HIGHLIGHTS Revenue for the six months ended June 30 , 2026 was RMB302.2 million ( US $ 44.5 million ) , compared to RMB233.7 million ( US $ 32.6 million ) for the six months ended June 30 , 2025 , which represents an increase of RMB68.5 million ( US $ 11.9 million ) , or 29.3 % on a constant exchange rate ( CER ) basis , as compared to the six months ended June 30 , 2025 , primarily because product sales increased by RMB69.5 million ( US $ 11.9 million ) , or 32.6 % , to RMB282.4 million ( US $ 41.6 million ) for the six months ended June 30 , 2026 , compared to RMB212.9 million ( US $ 29.7 million ) for the six months ended June 30 , 2025 . Total operating expenses for the six months ended June 30 , 2026 increased by RMB276.7 million ( US $ 46.7 million ) , or 36.1 % to RMB1,042.7 million ( US $ 153.7 million ) , as compared to the same period of 2025. Research and development expenses increased by RMB168.9 million ( US $ 29.0 million ) , or 32.0 % , to RMB697.5 million ( US $ 102.8 million ) for the six months ended June 30 , 2026 , compared to RMB528.6 million ( US $ 73.8 million ) for the six months ended June 30 , 2025 , primarily attributable to progress in our ongoing global clinical trials . Selling and distribution expenses increased by RMB88.6 million ( US $ 14.2 million ) , or 64.3 % , to RMB226.4 million ( US $ 33.4 million ) for the six months ended June 30 , 2026 , primarily attributable to increased marketing and promotion investment for Lisaftoclax . Net loss was RMB817.0 million ( US $ 120.4 million ) for the six months ended June 30 , 2026 , compared to loss of RMB590.8 million ( US $ 82.5 million ) for the six months ended June 30 , 2025 . As at June 30 , 2026 , the Group's cash and bank balances were RMB1,895.6 million ( US $ 279.4 million ) , or a decrease of RMB574.5 million ( US $ 73.8 million ) , or 23.3 % on a constant exchange rate ( CER ) basis compared with RMB2,470.1 million ( US $ 353.2 million ) as at December 31 , 2025 , which was primarily attributable to ongoing operating expenses associated with global clinical trials as well as research and development . 1